Last reviewed · How we verify
SK-PC-B70M
SK-PC-B70M is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens.
SK-PC-B70M is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens. Used for Melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).
At a glance
| Generic name | SK-PC-B70M |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Drug class | Cancer vaccine (personalized neoantigen vaccine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This drug is a personalized neoantigen-based cancer vaccine that uses patient-specific tumor mutations to generate targeted T-cell immune responses. It is intended to work synergistically with checkpoint inhibitors to enhance anti-tumor immunity by training the immune system to recognize and attack cancer cells expressing individual patient mutations.
Approved indications
- Melanoma (in combination with checkpoint inhibitors)
- Non-small cell lung cancer (in combination with checkpoint inhibitors)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
- A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease (PHASE3)
- A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |